Article Text

PDF
Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy
  1. Juan Pablo Kaski1,
  2. María Teresa Tomé Esteban1,
  3. Martin Lowe1,
  4. Simon Sporton2,
  5. Philip Rees1,
  6. John E Deanfield1,
  7. William J McKenna1,
  8. Perry M Elliott1
  1. 1Inherited Cardiovascular Diseases Unit, Great Ormond Street Hospital, London, UK
  2. 2St Bartholomew’s Hospital, London, UK
  1. Correspondence to:
    Dr P M Elliott
    The Heart Hospital, 16-18 Westmoreland Street, London W1G 8PH, UK; perry.elliott{at}uclh.nhs.uk

Statistics from Altmetric.com

Implantable cardioverter-defibrillators (ICDs) have been shown to successfully treat life-threatening arrhythmias in high-risk adults with hypertrophic cardiomyopathy (HCM).1 Children represent <1% of individuals with ICDs, and paediatric studies include few children with HCM. This study reports the experience with ICDs in children with HCM in a single referral centre.

METHODS

Between 1993 and February 2006, 160 consecutively referred patients with HCM (age ⩽16 years) underwent clinical evaluation using 12-lead ECG, two-dimensional, M-mode and Doppler echocardiography, Holter monitoring and cardiopulmonary exercise testing using previously described methods.2 Risk markers for sudden cardiac death (SCD) were: (1) family history of SCD; (2) unexplained syncope; (3) abnormal blood pressure response during upright exercise; (4) non-sustained ventricular tachycardia; and (5) severe left ventricular hypertrophy (⩾30 mm).2 Patients with previous cardiac arrest or with ⩾2 risk factors were considered for ICD implantation.2 All patients who underwent ICD implantation during this period were included in this study.

Informed consent for ICD implantation was obtained from a parent in all cases. Devices were implanted under general anaesthesia into subpectoral pockets, using transvenous lead systems. Sixteen patients received dual chamber devices and six received single-chamber devices. Stored ICD data were obtained every 6 months or within 24 h of treatment. Discharges were judged appropriate when triggered by ventricular tachycardia or ventricular fibrillation, or inappropriate if triggered by …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.